Diffuse Interstitial Pontine Glioma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Diffuse interstitial pontine glioma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Diffuse Interstitial Pontine Glioma Today - Breaking & Trending Today

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug. ....

United States , Jenene Thomas , Walter Klemp , Moleculin Biotech Inc , Company Investigational New Drug , Emory University , Drug Administration , Exchange Commission , Securities Exchange , Prnewswire Moleculin Biotech Inc , Investigational New Drug , Transcription Modulator , Regulatoryt Cells , Diffuse Interstitial Pontine Glioma , Orphan Drug Designation , Rare Pediatric Disease , Glioblastoma Multiforme , Moleculin Biotech , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Although Moleculin ,

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug. ....

United States , Jenene Thomas , Walter Klemp , Moleculin Biotech Inc , Company Investigational New Drug , Emory University , Drug Administration , Exchange Commission , Securities Exchange , Prnewswire Moleculin Biotech Inc , Investigational New Drug , Transcription Modulator , Regulatoryt Cells , Diffuse Interstitial Pontine Glioma , Orphan Drug Designation , Rare Pediatric Disease , Glioblastoma Multiforme , Moleculin Biotech , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Although Moleculin ,

Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug. ....

United States , United Kingdom , Jenene Thomas , Walter Klemp , Moleculin Biotech Inc , Exchange Commission , Prnewswire Moleculin Biotech Inc , Securities Exchange , Healthcare Products Regulatory Agency , Generation Anthracycline , Commence Phase , Transcription Modulators , Regulatoryt Cells , Cutaneoust Cell Lymphoma , Diffuse Interstitial Pontine Glioma , Glioblastoma Multiforme , New Drug , Glycosylation Inhibitor , Emergency Use Authorization , Drugs Controller General , Financial Results , Second Quarter , Moleculin Biotech , Transcription Modulator , Securities Act , Securities Exchange Act ,

Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update

Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update
- Multiple ongoing clinical studies expected to drive key clinical and regulatory milestones throughout next 18 months -
- Significantly strengthened financial position extends cash runway through 2023 -
News provided by
Share this article
HOUSTON, May 12, 2021 /PRNewswire/
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended March 31, 2021. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. ....

United States , Jenene Thomas , Walter Klemp , Moleculin Biotech Inc , Catalyst Clinical Research , Drug Administration , Exchange Commission , Prnewswire Moleculin Biotech Inc , Securities Exchange , Maria Sklodowska Curie National Research Institute , Rare Pediatric Disease Designation , Priority Review Voucher , Fast Track Designation , Generation Anthracycline , Commence Phase , Transcription Modulators , Regulatoryt Cells , Cutaneoust Cell Lymphoma , Diffuse Interstitial Pontine Glioma , Glioblastoma Multiforme , Facilitate Phase , Glycosylation Inhibitor , Emergency Use Authorization , Drugs Controller General , Financial Results , First Quarter ,